Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders

Table 4

Scenario sensitivity analyses results.

No.	Variable	Base case input value	Sensitivity input value	ICER (Cost (RM) per QALY gained)
1a	Undiscounted cost and outcomes	3%	0%	48,033
1b	5% discount rate	3%	5%	47,419
2a	3-year time horizon	60 years	3 years	25,438
2b	10-year time horizon	60 years	10 years	47,586
3a	High sevelamer dose	2.184g	4.8g	65,210
3b	High CaCO3 dose	2.95g	7.5g	47,325
4	Low dialysis utility	0.8	0.72	51,086
5a	Low HD cost	RM259.09	RM197.48	40,627
5b	High HD cost	RM259.09	RM350.00	58,084
6	Exclude dialysis cost	RM259.09	0	14,407